Drug intelligence / Profile preview

nonapeptide-1

Development stage
Preclinical
Lead developer
Lucas Meyer Cosmetics
Modality
Peptides
Administration
Topical
01

Overview

Nonapeptide-1 (also known as Melanostatine-5) is a synthetic biomimetic nonapeptide that acts as a selective, competitive antagonist of the melanocortin-1 receptor (MC1R). By blocking the binding of alpha-melanocyte-stimulating hormone (α-MSH) to MC1R on melanocytes, it inhibits the downstream cAMP/PKA signaling pathway, leading to the downregulation of microphthalmia-associated transcription factor (MITF) and key melanogenic enzymes such as tyrosinase. This prevents the hyperproduction of melanin and reduces skin pigmentation. Nonapeptide-1 is widely used as a skin-brightening and tone-correcting active ingredient in cosmetic formulations and is also utilized as a research tool in skin biology and pigmentation studies.

Brand names
Melanostatine 5Melanostatine5Melanostatine-5Melanostatine 5 BGMelanostatine5 BGMelanostatine-5 BG
Other names
Melanostatin-5Melanostatin5Melanostatin 5Melanostatine-5Melanostatine5Melanostatine 5Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH-2Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH 2nonapeptide-1 acetatenonapeptide1 acetatenonapeptide 1 acetate
02

Targets

MC1R (Melanocortin Type 1 Receptor)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)MC5R (Melanocortin 5 Receptor)TYR (Tyrosinase)

Beyond the preview

Go deeper on nonapeptide-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nonapeptide-1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call